O'Shaughnessy Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

O'Shaughnessy Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,807	Closed	-$39.3K	–	2808
2026 Q1	$39.3K	Buy	+12,807	New	+$49.5K	﹤0.01%	2264
2025 Q4	–	Sell	-13,356	Closed	-$65.2K	–	2727
2025 Q3	$65.2K	Buy	+13,356	New	+$70.1K	﹤0.01%	2153
2021 Q4	–	Sell	-208	Closed	-$5K	–	2235
2021 Q3	$5K	Buy	+208	New	+$5.89K	﹤0.01%	2344

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

O'Shaughnessy Asset Management's RXRX Position: Q2 2026 in Review

O'Shaughnessy Asset Management sold out of Recursion Pharmaceuticals (RXRX) in Q2 2026, closing a stake of 12,807 shares — an estimated $39.3K sold.

O'Shaughnessy Asset Management first reported a position in RXRX in Q3 2021 and held it in 3 quarters. The position peaked at $65.2K in Q3 2025. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

O'Shaughnessy Asset Management reported no remaining Recursion Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
O'Shaughnessy Asset Management sold 12,807 Recursion Pharmaceuticals shares in Q2 2026, an estimated $39.3K.
O'Shaughnessy Asset Management first reported a position in Recursion Pharmaceuticals in Q3 2021 and held it in 3 quarters.
O'Shaughnessy Asset Management's Recursion Pharmaceuticals position peaked at $65.2K in Q3 2025.
342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on O'Shaughnessy Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.